Name: Atebrioz (zilurgisertib) in Fibrodysplasia ossificans progressiva: Generic, brand name and therapeutic class of product
Published: 2026-09-27T12:28:00-04:00

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

4 evidence topics · 3 sources

Manufacturer: Mirum Pharmaceuticals

“Manufactured for: Mirum Pharmaceuticals, Inc., Foster City, CA 94404” (opens the prescribing information at this quote)
“Licensed from: Incyte Corporation, Wilmington, DE 19803” (opens the prescribing information at this quote)
“ATEBRIOZ is a trademark of Incyte.” (opens the prescribing information at this quote)

“Mirum Pharmaceuticals, Inc. licensed zilurgisertib from Incyte for worldwide development and commercialization.” (opens the source at this quote in a new tab)

Brand name, generic name, and therapeutic class

“ATEBRIOZ™ (zilurgisertib) tablets, for oral use” (opens the prescribing information at this quote)
“ATEBRIOZ is an activin receptor-like kinase-2 (ALK2) inhibitor indicated to reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP).” (opens the prescribing information at this quote)

Development code

“INCB00928 (zilurgisertib)” (opens the source at this quote in a new tab)
“In May 2022, we initiated a Phase 2 trial evaluating zilurgisertib (INCB00928) in patients with fibrodysplasia ossificans progressiva” (opens the source at this quote in a new tab)

Active moiety and salt form

“ATEBRIOZ contains the active moiety zilurgisertib, an activin receptor–like kinase-2 (ALK-2) inhibitor, in the form of zilurgisertib fumarate dihydrate.” (opens the prescribing information at this quote)